All adverse effects and severe adverse effects of erlotinib plus bevacizumab
| Adverse effects (all grades followed severe grades) | Erlotinib plus bevacizumab (event/total) | Erlotinib (event/total) | RR (95% CI) | P value | Heterogeneity | |
| I2 (%) | P value | |||||
| Rash | 280/344 | 292/344 | 0.98 (0.90 to 1.07) | 0.63 | 67 | 0.05 |
| Diarrhoea | 176/344 | 149/344 | 1.19 (1.03 to 1.38) | 0.02 | 49 | 0.14 |
| Paronychia | 102/344 | 97/344 | 1.06 (0.87 to 1.30) | 0.57 | 0 | 0.55 |
| Stomatitis | 95/344 | 75/344 | 1.32 (0.89 to 1.96) | 0.17 | 52 | 0.12 |
| Haemorrhagic event | 141/344 | 70/344 | 2.66 (1.12 to 6.31） | 0.03 | 89 | <0.001 |
| Proteinuria | 86/344 | 9/344 | 9.26 (4.86 to 17.66) | <0.0001 | 0 | 0.41 |
| Hypertension | 138/344 | 26/344 | 5.37 (3.66 to 7.88) | <0.0001 | 0 | 0.89 |
| Rash | 54/387 | 50/389 | 1.10 (0.78 to 1.56) | 0.59 | 0 | 0.69 |
| Diarrhoea | 15/387 | 9/389 | 1.67 (0.76 to 3.68) | 0.20 | 25 | 0.26 |
| Paronychia | 4/344 | 8/344 | 0.54 (0.17 to 1.66) | 0.28 | 0 | 0.75 |
| Stomatitis | 4/344 | 4/344 | 0.76 (0.17 to 3.36) | 0.71 | 0 | 0.91 |
| Haemorrhagic event | 6/344 | 1/344 | 3.52 (0.74 to 16.87) | 0.11 | 0 | 0.86 |
| Proteinuria | 30/387 | 1/389 | 12.75 (3.54 to 45.97) | <0.0001 | 0 | 0.95 |
| Hypertension | 117/387 | 18/389 | 5.00 (2.14 to 11.68) | 0.0002 | 71 | 0.02 |